| POLQ in Breast Cancer |
|
https://doi.org/10.18632/oncotarget.120
Adrian Begg
|
| 161-162 |
Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker
Phosphatidylcholine metabolic transformation and progression signature as a pharmacodynamic biomarker |
|
https://doi.org/10.18632/oncotarget.121
Eric O. Aboagye
|
| 163-166 |
Src and Abl hijack the Robo1 pathway
Src and Abl hijack the Robo1 pathway |
|
https://doi.org/10.18632/oncotarget.122
Christian Naus
|
| 167-167 |
Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma
Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma |
|
https://doi.org/10.18632/oncotarget.123
Sean M. Post,
Vinod Pant,
Hussein Abbas,
and Alfonso Quintás-Cardama
|
| 168-174 |
Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients
Overexpression of POLQ Confers a Poor Prognosis in Early Breast Cancer Patients |
|
https://doi.org/10.18632/oncotarget.124
Geoff S Higgins,
Adrian L Harris,
Remko Prevo,
Thomas Helleday,
W Gillies McKenna,
and Francesca M Buffa
|
| 175-184 |
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition
Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition |
|
https://doi.org/10.18632/oncotarget.125
Mounia Beloueche-Babari,
Vaitha Arunan,
L. Elizabeth Jackson,
Nina Perusinghe,
Swee Y. Sharp,
Paul Workman,
and Martin O. Leach
|
| 185-197 |
Src activates Abl to augment Robo1 expression in order to promote tumor cell migration
Src activates Abl to augment Robo1 expression in order to promote tumor cell migration |
|
https://doi.org/10.18632/oncotarget.126
P. Raaj Khusial,
Bhaskar Vadla,
Harini Krishnan,
Trudy F. Ramlall,
Yongquan Shen,
Hitoshi Ichikawa,
Jian-Guo Geng,
and Gary S. Goldberg
|
| 198-209 |
Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer
Jagged1 expression regulated by Notch3 and Wnt/β-catenin signaling pathways in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.127
Xu Chen,
Alexander Stoeck,
Soo Jung Lee,
Ie-Ming Shih,
Michael M. Wang,
and Tian-Li Wang
|
| 210-218 |
PEAK1, a Novel Kinase Target in the Fight Against Cancer
PEAK1, a Novel Kinase Target in the Fight Against Cancer |
|
https://doi.org/10.18632/oncotarget.128
Jonathan A. Kelber,
and Richard L. Klemke
|
| 219-223 |
Is miR-29 an oncogene or tumor suppressor in CLL?
Is miR-29 an oncogene or tumor suppressor in CLL? |
|
https://doi.org/10.18632/oncotarget.129
Yuri Pekarsky,
and Carlo M. Croce
|
| 224-227 |
Targeting Rb mutant cancers by inactivating TSC2
Targeting Rb mutant cancers by inactivating TSC2 |
|
https://doi.org/10.18632/oncotarget.130
Jennifer S. Searle,
Binghui Li,
and Wei Du
|
| 228-232 |
